TC
NVAX icon

TFS Capital’s Novavax NVAX Stock Holding History

TFS Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-871
Closed -$22K – 795
2016
Q4 		$22K Buy
+871
New +$25.4K 0.01% 708
2016
Q1 		– Sell
-629
Closed -$106K – 1066
2015
Q4 		$106K Buy
+629
New +$96.8K 0.01% 652
2015
Q1 		– Sell
-802
Closed -$95K – 1073
2014
Q4 		$95K Sell
802
-607
-43% -$63.4K 0.01% 915
2014
Q3 		$118K Buy
+1,409
New +$127K 0.01% 954
2013
Q4 		– Sell
-70,976
Closed -$4.47M – 1580
2013
Q3 		$4.47M Buy
70,976
+62,560
+743% +$3.52M 0.2% 116
2013
Q2 		$345K Buy
+8,416
New +$365K 0.01% 1076

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TFS Capital's NVAX Position: Q1 2017 in Review

TFS Capital sold out of Novavax (NVAX) in Q1 2017, closing a stake of 871 shares — an estimated $22K sold.

TFS Capital first reported a position in NVAX in Q2 2013 and held it in 6 quarters. The position peaked at $4.47M in Q3 2013. 129 funds tracked by Wall St. Rank hold NVAX as of Q1 2017.

  • TFS Capital reported no remaining Novavax position as of Q1 2017 after selling out during the quarter.
  • TFS Capital sold 871 Novavax shares in Q1 2017, an estimated $22K.
  • TFS Capital first reported a position in Novavax in Q2 2013 and held it in 6 quarters.
  • TFS Capital's Novavax position peaked at $4.47M in Q3 2013.
  • 129 funds tracked by Wall St. Rank held Novavax as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.